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Research articleMycobacterium tuberculosis PPD-induced immune 
biomarkers measurable in vitro following BCG 
vaccination of UK adolescents by multiplex bead 
array and intracellular cytokine staining
Steven G Smith*1, Maeve K Lalor1, Patricia Gorak-Stolinska1, Rose Blitz1, Natalie ER Beveridge2, Andrew Worth2, 
Helen McShane2 and Hazel M Dockrell1
Abstract
Background: The vaccine efficacy reported following Mycobacterium bovis Bacillus Calmette Guerin (BCG) 
administration to UK adolescents is 77% and defining the cellular immune response in this group can inform us as to 
the nature of effective immunity against tuberculosis. The aim of this study was to identify which cytokines and 
lymphocyte populations characterise the peripheral blood cellular immune response following BCG vaccination.
Results: Diluted blood from before and after vaccination was stimulated with Mycobacterium tuberculosis purified 
protein derivative for 6 days, after which soluble biomarkers in supernatants were assayed by multiplex bead array. Ten 
out of twenty biomarkers measured were significantly increased (p < 0.0025) 1 month after BCG vaccination when 
compared to paired samples (n = 12) taken prior to vaccination (IFNγ, TNFα, IL-1α, IL-2, IL-6, IL-10, IL-17, GM-CSF, MIP1α, 
IP-10). All of these remained detectable by multiplex bead array in samples taken 12 months after BCG vaccination of a 
partially overlapping adolescent group (n = 12). Intracellular cytokine staining after 24 hour Mycobacterium tuberculosis 
purified protein derivative stimulation of PBMC samples from the 12 month group revealed that IFNγ expression was 
detectable in CD4 and CD8 T-cells and natural killer cells. Polyfunctional flow cytometry analysis demonstrated that 
cells expressing IFNγ alone formed the majority in each subpopulation of cells. Only in CD4 T-cells and NK cells were 
there a notable proportion of responding cells of a different phenotype and these were single positive, TNFα 
producers. No significant expression of the cytokines IL-2, IL-17 or IL-10 was seen in any population of cells.
Conclusions: The broad array of biomarker responses detected by multiplex bead array suggests that BCG vaccination 
is capable, in this setting, of inducing a complex immune phenotype. Although polyfunctional T-cells have been 
proposed to play a role in protective immunity, they were not present in vaccinated adolescents who, based on earlier 
epidemiological studies, should have developed protection against pulmonary tuberculosis. This may be due to the 
later sampling time point available for testing or on the kinetics of the assays used.
Background
That the cytokine interferon gamma (IFNγ) plays an
important role in the protective immune response against
tuberculosis (TB) is indicated by the susceptibility of
mice and humans with IFNγ signalling pathway deficien-
cies to TB disease [1-3]. Its detection in isolation however
is not a sufficient indicator of a protective immune phe-
notype as those with latent infection and a positive IFNγ
release assay status can progress to active disease and
IFNγ secretion can also be detected in samples from
patients with active disease [4].
The Th-1-type immune response that is most effective
against TB and of which IFNγ is a component is likely to
include other cytokines such as tumour necrosis factor
alpha (TNFα), interleukin (IL) -2 and IL-12. A role for the
more recently identified Th-17 phenotype involving IL-
17 has also been described [5,6]. Furthermore, the pres-
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ence of cells that secrete such cytokines as well as other
immune effector molecules may be included as a compo-
nent of a protective biomarker profile. For example, CD4+
T-cells play an important role in TB immunity, however
CD8+, NKT and γδ T-cells may also be necessary [7-10].
A protective biomarker signature may also be defined by
the absence of particular biomarkers as certain immune
states may subvert the response to TB, allowing bacterial
infection to persist and for disease to eventually progress.
Cytokines such as IL-4 or other immunoregulatory
cytokines such as IL-10 derived from Th-2 biased T-cells
or regulatory T-cells respectively may indicate such a
subversion if detected [11,12].
BCG vaccination has previously demonstrated a pro-
tective efficacy of 77% against pulmonary tuberculosis
when administered to UK adolescents [13]. We have used
this setting to investigate the nature of the immunity
induced by BCG vaccination in representative cohorts of
UK schoolchildren (age range 12-15). Diluted whole
blood assays on samples from such a cohort, in which
responses to antigen during 6 day cultures were mea-
sured by quantifying IFNγ in assay supernatants, revealed
increased IFNγ after vaccination compared to that mea-
sured in pre-vaccination samples [14]. The status of IFNγ
as a cytokine that is necessary but not sufficient for pro-
tection against TB is illustrated by parallel experiments
carried out in Malawi where high concentrations of IFNγ
were detected both prior to and following BCG vaccina-
tion in a setting where BCG is much less protective than
in the UK [14]. Furthermore, studies have described other
biomarkers that can differentiate latent infection from
active disease [15] and have highlighted the importance
of cytokines such as TNFα [5,16]. Such observations
emphasise the need to measure a greater diversity of
potential biomarkers in order to develop a more detailed
representation of the BCG-induced immune response in
different settings. In South Africa, studies on samples
from BCG-vaccinated infants to look at responses com-
prising the Th-1 cytokines IFNγ, TNFα and IL-2 revealed
multiple T-cell phenotypes with distinct cytokine secre-
tion profiles [17]. Our group has also recently reported
extensive and complex cytokine responses measurable in
Mycobacterium tuberculosis purified protein derivative
(Mtb PPD)-stimulated blood from BCG-vaccinated, UK
infants [18]. New candidate TB vaccines that are thought
to represent more efficacious alternatives to BCG have
demonstrated the ability to induce populations of cells
with polyfunctional cytokine activity. The BCG/modified
Vaccinia Ankara-Ag85A vaccine regime, for example, can
generate CD4+ T-cells that secrete up to 4 cytokines
including IFNγ, TNFα, IL-2 and MIP-1β [19].
In the present study, we have used multiplex bead array
to determine the concentration of 20 biomarkers (includ-
ing cytokines and chemokines which together represent a
comprehensive coverage of possible immune phenotypes)
in the supernatants of Mtb PPD-stimulated, diluted
whole blood assays on samples from UK adolescents
taken prior to, and after BCG vaccination. A smaller
panel of biomarkers were further investigated by flow
cytometry. Cells from blood samples taken 12 months
after BCG vaccination were stimulated and stained with
antibodies to these biomarkers and other markers of T-
cell phenotype.
Results
Biomarkers detected by diluted whole blood assay and 
multiplex bead array analysis
We set out to determine the characteristics of the profile
of biomarkers present in peripheral blood from recently
BCG vaccinated individuals (n = 12). Blood samples
taken prior to and 1 month following BCG vaccination
were diluted with RPMI 1640 and cultured for 6 days in
the presence or absence of Mtb PPD. Assay supernatants
were collected and frozen, then later analysed for bio-
marker content by multiplex bead array. The average
sample storage time at ambient temperature between the
collection of blood samples at schools and laboratory
processing was 2.6 hours for both pre and 1 month post-
vaccination samples.
Of the 20 biomarkers that were measured, 10 were sig-
nificantly raised (p < 0.0025) in assays carried out on
samples taken 1 month after BCG vaccination (Figure 1
and Table 1). The majority of these were cytokines or
chemokines associated with an inflammatory response
(e.g. TNFα, IL-17, IL-1α, MIP1α, IL-6, IP-10) or the Th-1-
type immune response (IFNγ, IL-2). Also increased were
GM-CSF, and the anti-inflammatory cytokine IL-10.
There was some evidence of an increase in IL-13 (p =
0.049) although increased stringency in testing due to
multiple comparisons meant that this was not significant.
There was no significant increase at 1 month post-vacci-
nation in concentrations of IL-4 (p = 0.28), IL-8 (p = 0.09)
or G-CSF (p = 0.18). Analytes that were undetectable in
both pre and one month post vaccination samples were
IL-12p70, IL-7, IL-15, IL-5, IL-1β and eotaxin (Table 1).
IFNγ is considered an essential component of the
cytokine immune response to TB although not in itself
sufficient to represent a correlate of protection. We were
therefore interested in which biomarkers were associated
with IFNγ responses in these assays (Table 2). Compari-
sons between the magnitude of cytokine responses as
measured by concentration in assay supernatants
revealed that there was a correlation between the magni-
tude of IFNγ responses and those of other Th-1 or pro-
inflammatory biomarkers; TNFα (r = 0.91), MIP-1α (r =
0.87), IL-2 (r = 0.78), IL-17 (r = 0.77). There was also a
strong correlation between IFNγ and the growth factor
GM-CSF (r = 0.87) as well as with the anti-inflammatory
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Figure 1 Mtb PPD-specific cytokine/chemokine biomarker responses 1 month post BCG vaccination of UK adolescents. Plots representing 
concentrations of indicated biomarkers (see y-axis legends) are shown as measured by multiplex bead array assay on supernatants from 6 day diluted 
whole blood assays. Blood samples were donated from individuals (n = 12) prior to or 1 month following BCG vaccination. The dotted line indicates 
the lower limit of detection of the assay (3.2 pg/ml) and each data point represents the concentration measured in PPD-stimulated sample minus that 
measured in unstimulated sample. The Wilcoxon Signed Rank test was used to calculate p-values between pre and post-vaccination sample groups.
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cytokine IL-10 (r = 0.86). The weakest association with
IFNγ responses was shown by IP-10 (r = 0.19).
We next investigated whether biomarkers of interest
detected by multiplex early after BCG vaccination were
produced in response to stimulation at 12 months post-
vaccination. Due to loss to follow up at 12 months of
some individuals included in the pre-vaccination and 1
month analysis, the 12 samples analysed by multiplex at
12 months only partly overlap with the group analysed at
the earlier time point. They did however match the 12
month PBMC samples that were available for flow cyto-
metric analysis (see below). Using diluted, 6 day whole
blood assays with Mtb PPD stimulation and multiplex
bead array analysis a broad array of biomarkers remained
detectable with median responses above the assay's lower
limit of detection of 3.2 pg/ml (Table 3). Eight of the ten
biomarkers that were significantly raised in 1 month
post-BCG vaccination samples remained raised in 12
month samples. IL-6 and IL-10 returned to levels that
were comparable to those measured in pre-vaccination
samples. Unfortunately, following a company takeover
and the subsequent discontinuation of the original Linco-
plex kit, it was necessary to use Millipore's new Milliplex
version of the multiplex assay for 12 month sample analy-
sis. Due to some evidence of an increase in sensitivity for
some analytes and a decreased sensitivity for others, mea-
sured using the Milliplex kit compared to the Lincoplex
kit (data not shown), we did not consider it valid to draw
statistical comparisons between data collected using the
two kits. The 12 month data demonstrate however that,
within the parameters of the kit used, a broad array of
biomarkers remain detectable.
We conclude therefore, that BCG vaccination results in
a broad biomarker response measurable at one month in
peripheral blood that is detectable following Mtb PPD re-
stimulation. Furthermore, much of this broad response is
maintained until at least 12 months following vaccina-
tion.
Flow cytometric analysis of cellular cytokine production
At this stage, we utilised additional material available
from blood samples taken at the 12 month post-BCG
Table 1: Concentration (pg/ml) of 20 biomarkers measured prior to and 1 month after BCG vaccination of UK adolescents 
(values given are group median and interquartile range calculated after individual measurements were background 
corrected (PPD-stimulated - unstimulated values); n = 12)
Biomarker Pre-vaccination (PPD-
specific)
Pre-vaccination 
(background)
1 month post vaccination (PPD-
specific) (*p < 0.0025)
1 month post-vaccination 
(background)
IL-1α 50.6 (15.2-64.6) 8.0 86.9 (73.4-116.6)* 11.5
IL-1β 1.6 (1.6-1.6) 1.6 1.6 (1.6-1.6) 1.6
IL-2 1.6 (1.6-2.8) 1.6 8.0 (4.6-12.1)* 1.6
IL-4 1.6 (1.6-1.8) 1.6 6.8 (1.6-40.1) 1.6
IL-5 1.6 (1.6-1.6) 1.6 1.6 (1.6-3.9) 1.6
IL-6 310.0 (140.5-537.7) 1.6 751.6 (521.8-1018.0)* 3.8
IL-7 1.6 (1.6-1.6) 1.6 1.6 (1.6-1.6) 1.6
IL-8 728.1 (656.4-5678.0) 58.5 7534.0 (4082.0-23400.0) 66.2
IL-10 20.8 (4.7-61.4) 1.6 153.8 (93.8-279.3)* 1.6
IL-12p70 1.6 (1.6-1.6) 1.6 1.6 (1.6-1.6) 1.6
IL-13 1.6 (1.6-1.6) 2.8 10.3 (2.8-17.6) 2.4
IL-15 1.6 (1.6-1.6) 1.6 1.6 (1.6-1.6) 1.6
IL-17 2.6 (1.6-9.0) 1.6 72.3 (14.1-111.7)* 1.6
IFNγ 5.3 (1.6-79.6) 1.6 1273.0 (373.8-2815.0)* 1.6
TNF-α 23.0 (11.7-38.3) 2.6 105.2 (45.8-176.3)* 1.6
GM-CSF 21.0 (9.4-29.5) 4.3 125.7 (56.8-216.6)* 5.9
G-CSF 1.6 (1.6-2.7) 1.6 3.6 (1.6-19.6) 1.6
MIP-1α 8.3 (1.6-16.0) 1.6 54.6 (18.5-138.8)* 1.6
IP-10 548.6 (169.5-2881.0) 33.1 8866.0 (6901.0-15000.0)* 52.4
EOTAXIN 1.6 (1.6-6.5) 34.1 1.6 (1.6-4.1) 8.8
Statistical comparisons were made using the Wilcoxon Signed Rank test. Median background concentration of each biomarker measured in 
unstimulated wells is also shown.
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time point when PBMC were isolated and cryopreserved
(n = 12). Recovered cells were stimulated for 24 hours in
the presence or absence of Mtb PPD (plus Brefeldin A for
the final 6 hours) and stained with a panel of antibodies
recognising phenotypic lymphocyte markers and the
cytokines IFNγ, TNFα, IL-2, IL-17 and IL-10 before
acquisition.
Following gating on singlet and live cells and the exclu-
sion of CD14 or CD19-expressing cells, single cytokine
expression was examined in CD4 T-cells (CD3+CD4+
subset), CD8 T-cells (CD3+CD8+ subset) and natural
killer (NK) cells (CD3-CD56+ subset) (Figure 2A-C). IFNγ
expression was detected in all three subsets examined,
the median IFNγ-expressing proportion of each subset
being 0.03% (CD4 T-cells), 0.02% (CD8 T-cells) and 0.26%
(NK cells). TNFα expression was detected in CD4 T-cells
(0.03%) and NK cells (0.1%) however the median propor-
tion of CD8 T-cells expressing TNFα was very low
(<0.01%). Similarly, median expression levels of IL-2, IL-
17 and IL-10 after Mtb PPD stimulation were all less than
0.01%. Stimulation of cells with the positive control
Staphylococcus enterotoxin B (SEB) produced detectable
expression of IFNγ, TNFα, IL-2 and IL-17 but not IL-10
(Figure 2D).
Having detected both IFNγ and TNFα expression sepa-
rately in the CD4 T-cell and NK cell subsets we next
assessed to what extent expression of these two biomark-
ers was to be found in single, polyfunctional responders
(Figure 3). Although dot plots revealed that a small num-
ber of IFNγ and TNFα double positive CD4 T-cells and
NK cells were present in some individuals (Figure 3A),
the proportions of all CD4 T-cells or NK cells expressing
either cytokine that were in fact double positive in the
whole group was small (Figure 3B). The majority of
cytokine producing cells were only producing either IFNγ
or TNFα. For CD4 T-cells and to a greater extent NK
cells, IFNγ single positive cells comprised the largest pop-
ulation.
Taken together, these data demonstrate that in this
sample set, multiple cytokine responses are less readily
detectable by flow cytometry compared to the multiplex
bead array analysis involving a six day culture. Where
both Mtb PPD-specific IFNγ and TNFα expression was
detected in CD4 T-cells and NK cells it was mostly in sin-
gle cytokine producers rather than in cells of dual func-
tion.
Discussion
The cytokine response measured following BCG vaccina-
tion of adolescents in this study was broad. Such a varied
response was also observed by us and others in infant
studies of BCG vaccination [17,18]. Of 20 analytes mea-
sured, 10 were significantly raised in Mtb PPD stimu-
lated, diluted whole blood samples taken 1 month after
BCG vaccination compared to pre-vaccination samples.
IFNγ was the most markedly increased analyte (fold
increase of 240 in post-vaccination samples), which bears
out this cytokine's long-standing association with myco-
bacterial immunity [2,20]. TNFα and IL-2 have also both
been described by others as cytokines that are central to
Table 2: Correlation coefficients between the 
concentrations of IFNγ and other cytokines measured in 
whole blood assay supernatants one month after BCG 
vaccination
Biomarker Spearman correlation with IFNγ responses (r)
TNFα 0.91
GM-CSF 0.87
MIP-1α 0.87
IL-10 0.86
IL-2 0.78
IL-17 0.77
IL-6 0.69
IL-1α 0.56
IL-13 0.55
IP-10 0.19
Table 3: Concentration (pg/ml) of 20 biomarkers measured 
12 months after BCG vaccination of UK adolescents (values 
given are group median and interquartile range calculated 
after individual measurements were background corrected 
(PPD-stimulated - unstimulated values); n = 12)
Biomarker 12 months post vaccination
IL-1α 1710.0 (949.2-2008.0)
IL-1β 4.5 (1.6-10.1)
IL-2 8.2 (5.3-14.8)
IL-4 1.6 (1.6-1.8)
IL-5 1.6 (1.6-4.7)
IL-6 383.0 (198.7-1653.0)
IL-7 48.4 (36.2-95.6)
IL-8 6030.0 (521.8-11935.0)
IL-10 12.7 (10.2-22.2)
IL-12p70 1.9 (1.6-5.9)
IL-13 1.6 (1.6-6.9)
IL-15 1.6 (1.6-1.6)
IL-17 22.0 (3.0-37.8)
IFNγ 79.0 (37.9-239.1)
TNF-α 38.9 (26.9-140.0)
GM-CSF 147.7 (88.7-289.0)
G-CSF 3.8 (1.6-10.0)
MIP-1α 69.9 (27.0-279.3)
IP-10 4240.0 (2645.0-7670.0)
EOTAXIN 29.9 (23.7-37.1)
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effective immunity to TB [5,16] and indeed we found
them to be raised following BCG (increased by a factor of
4.6 and 5.0 respectively). The protection that has been
afforded against TB by BCG vaccination in the UK is
likely to rely on the actions of these cytokines. IFNγ and
TNFα can activate macrophages to better destroy phago-
cytosed Mtb [21] and TNFα helps induce maturation of
dendritic cells for more effective activation of mycobacte-
ria-specific T-cells [22]. IL-2 is also responsible for the
promotion of T-cell responses and memory [23]. Such
immune functions rely on the targeted release of these
cytokines by antigen experienced effector cells. That
BCG vaccination is priming such cells is indicated by our
observation that these biomarkers are detected at
increased concentrations in post-vaccination samples
after stimulation with Mtb PPD. The many other pro-
inflammatory biomarkers detected in post-vaccination
assay supernatants may represent a combined response
originating from Th-1 cells, blood monocytes or neutro-
phils that are responding to IFNγ and/or TNFα. It should
be noted that the inflammatory biomarkers IL-6, IL-8 and
IP-10, although increased in post-vaccination samples
were also present in relatively large amounts in pre-vacci-
nation samples following Mtb PPD stimulation. This sug-
gests an antigen-non-specific response of the innate
immune system, possibly as a result of stimulation of
monocytes or neutrophils via toll-like receptors by an
undefined component of the Mtb PPD protein cocktail.
This hypothesis requires further investigation. In addi-
tion, IL-8 and IP-10 were present in unstimulated wells to
Figure 2 Mtb PPD-specific cytokine expression in CD4 T-cells, CD8 T-cells and NK cells 12 months post BCG vaccination of UK adolescents. 
Box plots representing the proportion of A) CD4 T-cells, B) CD8 T-cells and C) NK cells that express the indicated cytokine (see x-axis labels) are shown 
as determined by intracellular cytokine staining of Mtb PPD-stimulated PBMC. D) CD4 T-cell cytokine expression in response to the positive control 
stimulant SEB. Cells were isolated from blood samples from individuals (n = 12) 12 months following BCG vaccination. The horizontal line represents 
the median response, the box represents the interquartile range and the whiskers represent the overall range.
A B
C D
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Figure 3 Polyfunctional analysis of Mtb PPD-specific cytokine expression in CD4 T-cells and NK cells 12 months post BCG vaccination of UK 
adolescents. A) Dot plots from one individual donor are shown comparing simultaneous expression of IFNγ (x-axis) and TNFα (y-axis). Previous gating 
was used to isolate singlet, live cells that were either CD3+CD4+ (CD4 T-cells) or CD3-CD56+ (NK cells) as indicated for each plot. Responses in unstim-
ulated and Mtb PPD-stimulated samples are shown. Values indicate the proportion (as a percentage) of the indicated subset present in that quadrant. 
B) Boolean gating and Spice analysis was used to determine the extent of polyfunctionality within the 12 month post-BCG vaccination group (n = 12). 
Bar charts represent, for either CD4 T-cells or NK cells, the median percentage (and interquartile range) of each subset expressing the indicated cy-
tokine combination (x-axis labels). Pie segments represent the average proportion, across the group, of cells expressing the indicated cytokine com-
bination (pie chart legend) within the total population of cells expressing either IFNγ or TNFα.
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a greater extent than other biomarkers suggesting that
these are released, to some degree in these conditions,
spontaneously.
IL-17 is a pro-inflammatory cytokine that has been
linked to a number of autoimmune and chronic inflam-
matory conditions such as rheumatoid arthritis [24] and
asthma [25]. In mice, γδ T-cell-derived IL-17 has been
demonstrated during Mtb and BCG infection and in the
latter, shown to contribute to effective Th-1 responses
and granuloma formation [26,27]. In our current study,
IL-17 was strongly increased in post-BCG whole blood
assay supernatants (28.3 fold increase) and was also sig-
nificantly associated with concurrent increases in IFNγ (r
= 0.769). As Mtb PPD comprises a number of undefined
components these results do not determine the precise
nature of the IL-17 response detected. Possibilities
include a CD4+ Th-17 response to protein antigen(s) in
Mtb PPD that are processed and presented by MHC class
II molecules. Alternatively, as there is evidence from
other studies that γδ T-cells may produce IL-17, it may be
that in our assay such cells are recognising an unknown
component of Mtb PPD.
If BCG vaccination of UK adolescents is taken as a set-
ting where there has been a degree of success in promot-
ing immunity to TB, it is surprising to see the anti-
inflammatory cytokine IL-10 also raised in Mtb PPD-
stimulated, post-BCG assay supernatants. It is possible
that the 6 day duration of the whole blood assay may
allow time for a complex network of physiological
homeostatic interactions between the cells present and
the cytokines released on stimulation with Mtb PPD. One
outcome of this may be the initiation of regulatory nega-
tive feedback loops that are characterised by the produc-
tion of IL-10.
Any biomarkers released upon an encounter with Mtb
antigen may originate from specific lymphocyte popula-
tions activated by vaccination. Although multiplex bead
array assays are a powerful tool, they cannot identify the
cellular source of any biomarkers measured. For this rea-
son we selected a smaller panel of biomarkers (IFNγ,
TNFα, IL-2, IL-17, IL-10) that could be assessed by flow
cytometry using specific monoclonal antibodies. When
combined with antibodies to phenotypic markers it was
possible to identify the cells that produced certain cytok-
ines. Due to availability, only PBMC from 12 month post-
BCG samples were available for flow cytometric analysis.
However, we used the multiplex assay to demonstrate
that many of the biomarker responses detectable at one
month remained detectable at 12 months.
In this study of Mtb-specific memory lymphocytes
induced by BCG, we detected predominantly single
cytokine producing cells when PBMC were stimulated for
24 hours with Mtb PPD. The largest responder phenotype
in each PBMC sub-population (CD4 T-cells, CD8 T-cells
and NK cells) was IFNγ single positive cells. NK cells and
CD4 T-cells also contained populations of TNFα single
positive responding cells, but double positive cells were
less common. For the CD8 T-cell population, single posi-
tive IFNγ cytokine secreting cells represented the only
notable responding cells. In a study of infant responses to
BCG vaccination from a TB-endemic country, analysis of
live BCG-stimulated whole blood samples showed that,
as in our study, within the CD8+ T-cell population, the
dominant population expressed IFNγ only [17]. However,
three other secretion patterns were also detected within
the CD8+ T-cells in that study; IL-2 only, IFNγ/TNFα/IL-
2 triple positive and IFNγ/IL-2 double positive cells
although these latter three patterns were at levels only
slightly above background. Such responses may be indic-
ative of the superior ability of live BCG over Mtb PPD to
stimulate CD8 T-cells as previously reported [28]. Also,
in contrast to our study, Soares et al detected 7 distinct
patterns of cytokine secretion within the CD4+ T-cell
population including triple, double and single positive
cytokine producers whereas we only observed 2 (IFNγ
and TNFα single positives). Using a PBMC stimulation
method similar to that described here, polyfunctional T-
cells (secreting up to four cytokines including IFNγ,
TNFα and IL-2) have been demonstrated following Mod-
ified Vaccinia Ankara-85A administration after previous
BCG vaccination of a UK cohort [19]. The lack of multi-
ple cytokine secreting cells in our study may be a result of
the late timing of these samples (12 months post-vaccina-
tion). Any polyfunctional, memory lymphocytes present
may exist only at very low frequencies that would require
the acquisition of many more events than were possible
in this study due to the amount of sample available.
Another possibility is that the exposure of responding
lymphocytes to antigen is minimal or absent 12 months
after BCG vaccination. Any multifunctional T-cells may,
as a result, convert to a resting state out of which the
short incubation time we used in flow cytometry assays is
insufficient to stimulate them. It should also be consid-
ered however, that the failure of BCG to deliver long-last-
ing (i.e. lifetime) immunity against pulmonary TB in
many settings may be predicted by the lack of induction
of long term polyfunctional T-cell responses as shown
here. Unfortunately, the lack of pre-vaccination or 1
month post-vaccination comparator samples for the flow
cytometry aspect of this study is a significant limitation
and renders us unable to comment on the absolute effect
of BCG vaccination on intracellular cytokine profiles. We
were unable to detect any expression of IL-2, IL-17 or IL-
10 by flow cytometry after Mtb PPD stimulation. Again,
this may be explained by the timing of the samples and
the need to acquire a large number of events to detect
very rare, cytokine producing cells. Soares et al. also
reported low percentages of IL-10 expressing T-cells that
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were, in most cases, below their cutoff for a positive
response [17]. The stimulation period used in that study
(12 hours) and in ours (24 hours) may be sub-optimal for
the detection of IL-10. Although we did not detect IL-17
after Mtb PPD stimulation, others have observed
CD3+CD4+IL-17+ cells following BCG and PPD stimula-
tion of whole blood from mycobacteria-exposed individ-
uals [29]. IL-17 induced by Mtb PPD was reported to be
low by Scriba et al and our use of purified PBMC as
opposed to their use of whole blood and the inherent
antigen processing differences involved may explain the
absence of IL-17+ cells in the current study. Others have
also found that purified T-cells with specificity for Mtb
PPD produced IFNγ but failed to produce IL-17 in
response to stimulation [30]. It should be noted that at 72
pg/ml, the median concentration of IL-17 measured by
multiplex bead array is relatively low in 1 month post-
BCG whole blood assay supernatants compared to IFNγ
(1273 pg/ml) and the increase over the median concen-
tration in pre-vaccination assays is only detectable due to
the sensitivity of the multiplex assay. Such marginal
secretion kinetics may be less easy to observe using a 24
hour flow cytometry assay at 12 months post BCG.
Conclusions
In summary, we have shown that the Mtb PPD-specific
response 1 and 12 months after BCG vaccination as mea-
sured in a 6 day, diluted whole blood assay was broad in
terms of cytokines released and encompassed Th-1 and
inflammatory mediators as well as immunoregulatory
elements. Such a multi-faceted response indicates the
complex nature of the immune response to BCG as well
as the ability to detect such responses in longer duration
assays. When Mtb PPD-stimulated PBMC were analysed
by flow cytometry, polyfunctional CD8 or CD4 T-cells
were not detected. The majority of responding cells in
these populations and especially in the NK cell popula-
tion were single cytokine (either IFNγ or TNFα) produc-
ers. Although these findings may relate to sample sizes,
timings and assay kinetics they may also represent an
inability of BCG to induce the polyfunctional T-cells that
are thought to be important mediators of immunity
against infection [31]. Whether such cells are detectable
earlier following vaccination and are lost at later time
points remains to be seen.
Methods
Subjects
Informed, written consent was obtained from the parents
of healthy UK adolescents due to receive tuberculin
(Heaf) skin testing and BCG vaccination as part of the
UK schools BCG programme. Verbal consent was given
by volunteers and ethical approval was obtained from the
Redbridge and Waltham Forest National Health Service
Local Research Ethics Committee and from the London
School of Hygiene & Tropical Medicine internal Ethics
Committee. Year 8 adolescents (12-13 years old) were
invited to take part and exclusion was based on evidence
previous of BCG vaccination (BCG scar or subsequent
positive tuberculin skin test).
Blood samples
Ten mL venous blood samples were taken from adoles-
cent study participants (subject to availability for
venepuncture) prior to tuberculin skin testing and again
at 1 month (the peak of the PPD-specific response follow-
ing BCG vaccination [32]) and 12 months after vaccina-
tion with BCG-Danish (Statens Serum Institute,
Copenhagen). Blood samples were transferred to 15 mL
centrifuge tubes (Greiner, Germany) containing 100 units
of preservative free heparin sodium (Monoparin, CP
Pharmaceuticals, UK). These were stored at room tem-
perature for transportation to the laboratory.
Diluted whole blood assay
Venous blood was diluted 1 in 10 in RPMI 1640 medium
(Invitrogen, UK) containing 2 mM L-glutamine (Invitro-
gen, UK) and cultured in 96-well U-bottomed tissue cul-
ture plates (Corning, USA) in a final volume of 200 μL
with or without stimulation. Antigen Mtb PPD (Statens
Serum Institute, Denmark)) was used at a concentration
of 5 μg/mL. Cultures were incubated for 6 days in humid-
ified incubators at 37°C, 5% CO2 after which culture
supernatants were collected and stored at -80°C.
Multiplex bead array
Twenty-one cytokines and chemokines were measured
simultaneously in culture supernatant from assays car-
ried out on samples obtained prior to and 1 month after
BCG vaccination using a human cytokine Lincoplex pre-
mixed kit according to the manufacturer's instructions
(cat #HCYTO-60K-PMX, Linco Research Inc, St Charles
Missouri, USA): IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-1α, IFNγ, G-CSF,
GM-CSF, TNFα, Eotaxin, MCP-1, MIP1α and IFNγ
inducible protein (IP)-10. Unstimulated and Mtb PPD
stimulated samples were read on the Biorad Luminex
reader using Bioplex manager 4.1 software. For each
cytokine the standard curve ran from 3.2 to 10,000 pg/ml.
Supernatants collected from assays carried out on sam-
ples obtained 12 months after BCG vaccination were
tested on a separate occasion using a human cytokine/
chemokine Milliplex™ MAP premixed kit according to
the manufacturer's instructions (cat #MPXHCYTO-60K-
PMX-42, Millipore Corp, St Charles Missouri, USA).
PBMC preparation and cryopreservation
PBMC were isolated from venous blood samples
obtained 12 months post-BCG vaccination. Blood was
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added to 50 mL Leucosep tubes (Greiner, Germany) con-
taining 15 mL Histopaque 1077 (Sigma, UK). Tubes were
centrifuged for 10 minutes at 1000 g. The PBMC layer
was transferred into fresh 15 mL centrifuge tubes,
washed 3 times in HBSS (Invitrogen, UK) and cells
counted. PBMC were frozen at 5 × 106 cells per ml of cry-
opreservation medium (45% RPMI 1640, 45% FBS, 10%
DMSO) using a Mr Frosty™ container (Nalgene) over-
night at -80°C before transfer to liquid nitrogen.
Intracellular cytokine staining
PBMC were thawed and incubated for 10 minutes at 37°C
in AIM-V medium (Invitrogen, UK) containing 10 units/
ml DNAse (Sigma), then washed and resuspended at 106
cells per ml in AIM-V. Depending on availability, between
5 × 105 and 106 cells were incubated for 24 hours in 15 ml
polypropylene centrifuge tubes at 37°C with either
medium alone, Mtb PPD at 10 μg/ml or positive control
Staphylococcus enterotoxin B (SEB; Sigma) at 1 μg/ml.
Brefeldin A was added to a concentration of 10 μg/ml for
the final 6 hours of incubation. The contents of each cen-
trifuge tube were transferred to 2.5 ml polystyrene flow
cytometer tubes (Falcon), washed with PBS containing
1% BSA and 0.1% sodium azide and stained with the
VIVID live/dead reagent (Molecular Probes) and conju-
gated monoclonal antibodies: anti-CD3-AmCyan; anti-
CD56-PE-Cy5 (BD Biosciences); anti-CD4-Qdot®605
(Invitrogen); anti-CD8-APC-Alexa Fluor®750; anti-CD14-
PacificBlue (Caltag Laboratories) and anti-CD19-Paci-
ficBlue (eBiosciences). After further washing and perme-
abilisation with Cytofix/cytoperm reagent (BD
Biosciences), cells were further stained with conjugated
monoclonal antibodies: anti-IFNγ-Alexa Fluor®700 (BD
Biosciences); anti-TNFα, PE-Cy7; anti-IL-2-APC; anti-IL-
17-PE (eBiosciences) and anti-IL-10-FITC (Caltag Labo-
ratories). Cells were finally washed and fixed with 1%
paraformaldehyde before acquisition using an LSRII flow
cytometer (Becton Dickinson) and FACSdiva software.
Compensation was achieved using BD™ CompBeads (BD
Biosciences). Between 2 × 105 and 6 × 105 total events
(mean 3.5 × 105) were acquired per sample (CD3+CD4+
mean acquired events - 9 × 104; CD3+CD8+ mean
acquired events - 4 × 104; CD3-CD56+ mean acquired
events - 3 × 104). Collected data was analysed using
FlowJo software (Version 8.8.1; Tree Star Inc.) and the
data analysis programs Pestle (version 1.6.1) and Simpli-
fied Presentation of Incredibly Complex Evaluations
(SPICE, version 4.3) kindly provided by Mario Roederer,
Vaccine Research Center, NIAID, NIH.
Data analysis
For multiplex bead array assays, for each donor, bio-
marker concentrations measured in unstimulated assays
were subtracted from those measured in Mtb PPD stimu-
lated assays. One in ten dilutions of supernatants were
also tested in some cases and these corrected values were
used when neat samples were beyond the assay's upper
limit of detection. Corrected values that were less than
the assay's lower limit of detection (3.2 pg/ml) were allo-
cated a value half this amount of 1.6 pg/ml representing
an undetectable response as previously described
[18,33,34]. For samples where the concentration of a par-
ticular biomarker was above the limit of detection, values
were assigned based on the highest detectable concentra-
tion for that biomarker in other samples (30,000 pg/ml
for IL-8 and 15,000 pg/ml for IP-10). Due to a large num-
ber of samples with unreadable MCP-1 concentrations,
this biomarker was omitted from further analyses.
For flow cytometry, CD19+ (B-cells) and CD14+ (mono-
cytes) events appeared in the same channel as VIVID
live/dead positive events (dead cells) and were together
negatively gated out of the analysis. Remaining
CD3+CD4+ (CD4 T-cells), CD3+CD8+ (CD8 T-cells) and
CD3-CD56+ (NK cells) events were analysed for cytokine
expression. Expression levels in unstimulated samples
were subtracted from those measured in Mtb PPD-stimu-
lated samples. The Boolean gate function of FlowJo was
used to create outputs for all possible cytokine expression
combinations using individual cytokine analysis gates
described above.
Statistical analysis
The Wilcoxon Signed Rank test was used to compare
cytokine/chemokine responses in paired samples from
pre-vaccination and 1 month post vaccination time
points. The test for significance was set at p < 0.0025 to
allow for multiple comparisons. Spearman's rank correla-
tion coefficient was calculated to compare the association
between IFNγ and other biomarkers measured 1 month
after vaccination.
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